Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury.

PPAR Res · 2012 · PMC3289925 · PMID 22448163

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

showed a trendno p-value reported

Rosiglitazone Fails to Improve Renal Function Significantly in Moderate I/R Injury In an in vivo model of renal I/R injury caused by an ischemic period of 45 min, treatment with rosiglitazone showed a trend towards improvement of renal functional parameters (GFR, RPF) but failed to reach statistical significance (data not shown).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.